https://www.ncbi.nlm.nih.gov/pubmed/31181021 Cystic fibrosis
J Pediatr Gastroenterol Nutr. 2019 Jun 7. doi: 10.1097/MPG.0000000000002413. [Epub ahead of print]
Liver Ultrasound Patterns in Children with Cystic Fibrosis Correlate with Non-Invasive Tests of Liver Disease.
Ling SC1, Ye W2, Leung DH3, Navarro OM4, Weymann A5, Karnsakul W6, Freeman AJ7, Magee JC8, Narkewicz MR9.
Abstract
OBJECTIVES:
Early identification of children with cystic fibrosis (CF) at risk for severe liver disease (CFLD) would enable targeted study of preventative therapies. There is no gold standard test for CFLD. Ultrasonography (US) is used to identify CFLD, but with concerns for its diagnostic accuracy. We aim to determine if differences in standard blood tests, imaging variables and non-invasive liver fibrosis indices correlate with liver US patterns and thus provide supportive evidence that a heterogeneous US liver pattern reflects clinically relevant liverdisease.
METHODS:
We studied baseline research abdominal US and bloodwork from 244 children with pancreatic insufficient CF, ages 3-12y, enrolled in a prospective study of the ability of US to predict CF cirrhosis (PUSH study). Children with a heterogeneous liver pattern on US (HTG, n = 62) were matched 1:2 in design with children with normal US (NL, n = 122). Analyses included children with nodular (NOD, n = 22) and homogeneous hyperechoic (HMG, n = 38) livers.
RESULTS:
Univariate analysis showed significant differences between US groups for standard blood tests, spleen size, and non-invasive liverfibrosis indices. Multivariable models discriminated NOD vs. NL with excellent accuracy (AUROC 0.96). Models also distinguish HTG vs. NL (AUROC 0.76), NOD vs. HTG (0.78), and HMG vs NL (0.79).
CONCLUSION:
Liver US patterns in children with CF correlate with platelet count, spleen size and indices of liver fibrosis. Multivariable models of these biomarkers have excellent discriminating ability for NL vs NOD, and good ability to distinguish other US patterns, suggesting that US patterns correlate with clinically relevant liver disease.